Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Venous Thrombosis

Free Subscription Articles published in Thromb Haemost Retrieve available abstracts of 139 articles: HTML format

Single Articles

May 2020
1. QUEZADA A, Jimenez D, Bikdeli B, Muriel A, et al
   Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation.
   Thromb Haemost. 2020 May 18. doi: 10.1055/s-0040-1710589.
   PubMed     Abstract available
   
   
   
2. GIUSTOZZI M, Agnelli G, Del Toro-Cervera J, Klok FA, et al
   Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
   Thromb Haemost. 2020 May 4. doi: 10.1055/s-0040-1712098.
   PubMed     Abstract available
   
   
   
3. GIUSTOZZI M, Curcio A, Weijs B, Field TS, et al
   Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer.
   Thromb Haemost. 2020;120:847-856.
   PubMed     Abstract available
   
   
   
4. BETENSKY M, Mueller MG, Amankwah EK, Goldenberg NA, et al
   In Children with Provoked Venous Thromboembolism, Increasing Plasma Coagulability during the First 3 Months Postdiagnosis is Prognostic of Recurrence.
   Thromb Haemost. 2020;120:823-831.
   PubMed     Abstract available
   
   
   
5. ALBERTSEN IE, Sogaard M, Goldhaber SZ, Piazza G, et al
   Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study.
   Thromb Haemost. 2020;120:805-814.
   PubMed     Abstract available
   
   
   
6. XU K, Chan NC
   Refining Risk Prediction for Recurrent Venous Thromboembolism: Can We Do Better?
   Thromb Haemost. 2020;120:725-727.
   PubMed    
   
   
   April 2020
7. CATTANEO M, Bertinato EM, Birocchi S, Brizio C, et al
   Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
   Thromb Haemost. 2020 Apr 29. doi: 10.1055/s-0040-1712097.
   PubMed    
   
   
   
8. ZHAI Z, Li C, Chen Y, Gerotziafas G, et al
   Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.
   Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019.
   PubMed     Abstract available
   
   
   
9. BARCO S, Konstantinides SV
   Predicting Venous Thromboembolism in Primary Care.
   Thromb Haemost. 2020;120:531-533.
   PubMed    
   
   
   
10. ABDULLA A, Davis WM, Ratnaweera N, Szefer E, et al
    A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer.
    Thromb Haemost. 2020;120:702-713.
    PubMed     Abstract available
    
    
    
11. DENTALI F, Fontanella A, Cohen AT, Simonetti M, et al
    Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care.
    Thromb Haemost. 2020;120:692-701.
    PubMed     Abstract available
    
    
    
12. MARCHENA PJ, Tzoran I, Brenner B, Martin M, et al
    Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.
    Thromb Haemost. 2020;120:620-626.
    PubMed     Abstract available
    
    
    February 2020
13. WEI WT, Liu PP, Lin SM, Peng CC, et al
    Hypothyroidism and the Risk of Venous Thromboembolism: A Nationwide Cohort Study.
    Thromb Haemost. 2020 Feb 6. doi: 10.1055/s-0039-3402761.
    PubMed     Abstract available
    
    
    
14. KOOPMANS RJ, Cannegieter SC, Koot RW, Vleggeert-Lankamp CLA, et al
    Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study.
    Thromb Haemost. 2020 Feb 6. doi: 10.1055/s-0039-3402732.
    PubMed     Abstract available
    
    
    January 2020
15. WEYCKER D, Li X, Wygant GD, Lee T, et al
    Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Thromb Haemost. 2020 Jan 27. doi: 10.1055/s-0039-3400530.
    PubMed    
    
    
    
16. HARENBERG J, Verhamme P
    The Dangerous Liaisons between Chronic Obstructive Pulmonary Disease and Venous Thromboembolism.
    Thromb Haemost. 2020 Jan 23. doi: 10.1055/s-0039-1701012.
    PubMed    
    
    
    
17. WALDEN K, Jeppsson A, Nasic S, Karlsson M, et al
    Fibrinogen Concentrate to Cardiac Surgery Patients with Ongoing Bleeding does not Increase the Risk of Thromboembolic Complications or Death.
    Thromb Haemost. 2020 Jan 15. doi: 10.1055/s-0039-3402759.
    PubMed     Abstract available
    
    
    
18. AL-ANI F, Wang YP, Lazo-Langner A
    Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia.
    Thromb Haemost. 2020 Jan 1. doi: 10.1055/s-0039-3400303.
    PubMed     Abstract available
    
    
    December 2019
19. BORVIK T, Braekkan SK, Evensen LH, Brodin EE, et al
    Chronic Obstructive Pulmonary Disease and Risk of Mortality in Patients with Venous Thromboembolism-The Tromso Study.
    Thromb Haemost. 2019 Dec 30. doi: 10.1055/s-0039-3400744.
    PubMed     Abstract available
    
    
    
20. SCHINDEWOLF M, Weitz JI
    Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment.
    Thromb Haemost. 2019 Dec 13. doi: 10.1055/s-0039-3400302.
    PubMed     Abstract available
    
    
    November 2019
21. PELARGOS PE, Dunn IF
    Venous Thromboembolism Prophylaxis: Safe, but Still Provocative?
    Thromb Haemost. 2019;119:1716-1718.
    PubMed    
    
    
    
22. KHORANA AA
    Modeling Complexity: The Case of Cancer-Related Venous Thromboembolism.
    Thromb Haemost. 2019;119:1713-1715.
    PubMed    
    
    
    October 2019
23. ISAKSEN T, Evensen LH, Braekkan SK, Hansen JB, et al
    Dietary Intake of Marine Polyunsaturated n-3 Fatty Acids and Risk of Recurrent Venous Thromboembolism.
    Thromb Haemost. 2019 Oct 28. doi: 10.1055/s-0039-1697663.
    PubMed     Abstract available
    
    
    
24. LIN SY, Chang YL, Yeh HC, Lin CL, et al
    Blood Transfusion and Risk of Venous Thromboembolism: A Population-Based Cohort Study.
    Thromb Haemost. 2019 Oct 22. doi: 10.1055/s-0039-1697664.
    PubMed     Abstract available
    
    
    
25. SQUIZZATO A, Agnelli G, Campanini M, Dentali F, et al
    Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study.
    Thromb Haemost. 2019 Oct 21. doi: 10.1055/s-0039-1697661.
    PubMed     Abstract available
    
    
    
26. PETERSEN PB, Jorgensen CC, Kehlet H
    Venous Thromboembolism despite Ongoing Prophylaxis after Fast-Track Hip and Knee Arthroplasty: A Prospective Multicenter Study of 34,397 Procedures.
    Thromb Haemost. 2019 Oct 6. doi: 10.1055/s-0039-1696686.
    PubMed     Abstract available
    
    
    
27. ERICKSON RM, Feehan M, Munger MA, Tak C, et al
    Understanding Factors Associated with Quality of Life in Patients with Venous Thromboembolism.
    Thromb Haemost. 2019 Oct 6. doi: 10.1055/s-0039-1696717.
    PubMed     Abstract available
    
    
    
28. SCHELLONG SM, Goldhaber SZ, Weitz JI, Ageno W, et al
    Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry.
    Thromb Haemost. 2019;19:1675-1685.
    PubMed     Abstract available
    
    
    August 2019
29. BIKDELI B, Visvanathan R, Jimenez D, Monreal M, et al
    Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis.
    Thromb Haemost. 2019 Aug 20. doi: 10.1055/s-0039-1693464.
    PubMed     Abstract available
    
    
    July 2019
30. XIE J, Jiang M, Lin Y, Deng H, et al
    Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients.
    Thromb Haemost. 2019 Jul 31. doi: 10.1055/s-0039-1693460.
    PubMed     Abstract available
    
    
    
31. MANDERSTEDT E, Lind-Hallden C, Svensson P, Zoller B, et al
    Next-Generation Sequencing of 17 Genes Associated with Venous Thromboembolism Reveals a Deficit of Non-Synonymous Variants in Procoagulant Genes.
    Thromb Haemost. 2019 Jul 28. doi: 10.1055/s-0039-1693130.
    PubMed     Abstract available
    
    
    June 2019
32. KIM K, Yamashita Y, Morimoto T, Kitai T, et al
    Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry.
    Thromb Haemost. 2019 Jun 23. doi: 10.1055/s-0039-1692425.
    PubMed     Abstract available
    
    
    
33. RAJ L, Robin P, Le Mao R, Presles E, et al
    Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice-The PADIS-PE Trial.
    Thromb Haemost. 2019 Jun 23. doi: 10.1055/s-0039-1692424.
    PubMed     Abstract available
    
    
    
34. JIANG X, Du Y, Cheng CY, Denas G, et al
    Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients.
    Thromb Haemost. 2019 Jun 21. doi: 10.1055/s-0039-1692428.
    PubMed     Abstract available
    
    
    
35. SEJRUP JK, Borvik T, Grimnes G, Isaksen T, et al
    Myocardial Infarction as a Transient Risk Factor for Incident Venous Thromboembolism: Results from a Population-Based Case-Crossover Study.
    Thromb Haemost. 2019 Jun 16. doi: 10.1055/s-0039-1692176.
    PubMed     Abstract available
    
    
    
36. KOLMEL S, Hobohm L, Kaberich A, Krieg VJ, et al
    Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension.
    Thromb Haemost. 2019 Jun 10. doi: 10.1055/s-0039-1692174.
    PubMed     Abstract available
    
    
    April 2019
37. JOHNSEN SP, Frost L
    Swimming Upstream: Disentangling the Association between Alcohol Intake and Venous Thromboembolism.
    Thromb Haemost. 2019 Apr 23. doi: 10.1055/s-0039-1687881.
    PubMed    
    
    
    
38. SHAYA SA, Gani DM, Weitz JI, Kim PY, et al
    Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi.
    Thromb Haemost. 2019 Apr 20. doi: 10.1055/s-0039-1685141.
    PubMed     Abstract available
    
    
    
39. NTAIOS G, Lip GYH
    Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades.
    Thromb Haemost. 2019 Apr 4. doi: 10.1055/s-0039-1685454.
    PubMed    
    
    
    
40. XU K, Chan NC, Ibrahim Q, Kruger P, et al
    Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis.
    Thromb Haemost. 2019;119:668-674.
    PubMed     Abstract available
    
    
    March 2019
41. JOHANSSON M, Johansson L, Wennberg M, Lind M, et al
    Alcohol Consumption and Risk of First-Time Venous Thromboembolism in Men and Women.
    Thromb Haemost. 2019 Mar 21. doi: 10.1055/s-0039-1681100.
    PubMed     Abstract available
    
    
    
42. DUFFETT L, Kearon C, Rodger M, Carrier M, et al
    Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis.
    Thromb Haemost. 2019;119:479-489.
    PubMed     Abstract available
    
    
    
43. LI L, Wu X, Wu W, Ding Q, et al
    Clinical Manifestation and Mutation Spectrum of 53 Unrelated Pedigrees with Protein S Deficiency in China.
    Thromb Haemost. 2019;119:449-460.
    PubMed     Abstract available
    
    
    February 2019
44. WEITZ JI, Chan NC
    Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.
    Thromb Haemost. 2019 Feb 26. doi: 10.1055/s-0039-1679906.
    PubMed     Abstract available
    
    
    
45. FOLSOM AR, Tang W, Basu S, Misialek JR, et al
    Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population.
    Thromb Haemost. 2019 Feb 19. doi: 10.1055/s-0039-1678737.
    PubMed     Abstract available
    
    
    
46. BARCO S, Granziera S, Coppens M, Douxfils J, et al
    Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.
    Thromb Haemost. 2019 Feb 7. doi: 10.1055/s-0039-1678546.
    PubMed     Abstract available
    
    
    
47. SUGIURA-OGASAWARA M, Ebara T, Matsuki T, Yamada Y, et al
    Endometriosis and Recurrent Pregnancy Loss as New Risk Factors for Venous Thromboembolism during Pregnancy and Post-Partum: The JECS Birth Cohort.
    Thromb Haemost. 2019 Feb 5. doi: 10.1055/s-0039-1677733.
    PubMed     Abstract available
    
    
    January 2019
48. REZIG S, Mao RL, Couturaud F, Lacut K, et al
    Incidence of Cancer after a Second Unprovoked Venous Thromboembolic Event.
    Thromb Haemost. 2019 Jan 27. doi: 10.1055/s-0039-1677745.
    PubMed     Abstract available
    
    
    
49. COHEN AT, Agnelli G, Buller HR, Gallus A, et al
    Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Thromb Haemost. 2019 Jan 16. doi: 10.1055/s-0038-1676983.
    PubMed     Abstract available
    
    
    
50. KOSTRUBIEC M, Plywaczewska M, Jimenez D, Lankeit M, et al
    The Prognostic Value of Renal Function in Acute Pulmonary Embolism-A Multi-Centre Cohort Study.
    Thromb Haemost. 2019;119:140-148.
    PubMed     Abstract available
    
    
    
51. ZOLLER B, Pirouzifard M, Sundquist J, Sundquist K, et al
    Association of Short-Term Mortality of Venous Thromboembolism with Family History of Venous Thromboembolism and Charlson Comorbidity Index.
    Thromb Haemost. 2019;119:48-55.
    PubMed     Abstract available
    
    
    
52. SAMAMA CM
    Fast-Track Procedures in Major Orthopaedic Surgery: Is Venous Thromboembolism Prophylaxis Still Mandatory?
    Thromb Haemost. 2019;119:3-5.
    PubMed    
    
    
    
53. PENG S, Xue G, Chen S, Chen Z, et al
    tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity.
    Thromb Haemost. 2019;119:77-86.
    PubMed     Abstract available
    
    
    December 2018
54. AGENO W, Haas S, Weitz JI, Goldhaber SZ, et al
    Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.
    Thromb Haemost. 2018 Dec 28. doi: 10.1055/s-0038-1676611.
    PubMed     Abstract available
    
    
    November 2018
55. PIAZZA G
    Oh Heavy Burden: Recognizing the Risk of Venous Thromboembolism in Women Undergoing Assisted Reproduction.
    Thromb Haemost. 2018 Nov 19. doi: 10.1055/s-0038-1676073.
    PubMed    
    
    
    
56. WEYCKER D, Li X, Wygant GD, Lee T, et al
    Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Thromb Haemost. 2018;118:1951-1961.
    PubMed     Abstract available
    
    
    October 2018
57. BORRE ED, Goode A, Raitz G, Shah B, et al
    Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.
    Thromb Haemost. 2018 Oct 30. doi: 10.1055/s-0038-1675400.
    PubMed     Abstract available
    
    
    
58. MONREAL M
    Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
    Thromb Haemost. 2018 Oct 17. doi: 10.1055/s-0038-1675241.
    PubMed    
    
    
    
59. PASTORI D, Violi F
    Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?
    Thromb Haemost. 2018 Oct 12. doi: 10.1055/s-0038-1675176.
    PubMed    
    
    
    
60. ROETKER NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, et al
    Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673613.
    PubMed     Abstract available
    
    
    
61. GRANDONE E, Di Micco PP, Villani M, Colaizzo D, et al
    Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673402.
    PubMed     Abstract available
    
    
    
62. GRILZ E, Posch F, Konigsbrugge O, Schwarzinger I, et al
    Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer.
    Thromb Haemost. 2018 Oct 8. doi: 10.1055/s-0038-1673401.
    PubMed     Abstract available
    
    
    
63. ALBERTSEN IE, Nielsen PB
    Searching for High-Risk Venous Thromboembolism Patients Using Risk Scores: Adding to the Heap or Closing a Gap?
    Thromb Haemost. 2018;118:1686-1687.
    PubMed    
    
    
    August 2018
64. AGNELLI G, Becattini C, Bauersachs R, Brenner B, et al
    Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668523.
    PubMed     Abstract available
    
    
    
65. ROETKER NS, Lutsey PL, Zakai NA, Alonso A, et al
    All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668521.
    PubMed     Abstract available
    
    
    
66. PELLAND-MARCOTTE MC, Pole JD, Kulkarni K, Athale U, et al
    Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study.
    Thromb Haemost. 2018 Aug 13. doi: 10.1055/s-0038-1668543.
    PubMed     Abstract available
    
    
    
67. KRAAIJPOEL N, Di Nisio M, Mulder FI, van Es N, et al
    Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Thromb Haemost. 2018;118:1439-1449.
    PubMed     Abstract available
    
    
    
68. JIMENEZ D, Bikdeli B
    Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?
    Thromb Haemost. 2018;118:1343-1344.
    PubMed    
    
    
    July 2018
69. PETTERSON TM, Smith CY, Emerson JA, Bailey KR, et al
    Venous Thromboembolism (VTE) Incidence and VTE-Associated Survival among Olmsted County Residents of Local Nursing Homes.
    Thromb Haemost. 2018;118:1316-1328.
    PubMed     Abstract available
    
    
    June 2018
70. KRAAIJPOEL N, van Es N, Raskob GE, Buller HR, et al
    Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2018 Jun 4. doi: 10.1055/s-0038-1649523.
    PubMed     Abstract available
    
    
    April 2018
71. FRERE C, Trujillo-Santos J, Font C, Samperiz A, et al
    Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry.
    Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.
    PubMed    
    
    
    
72. BAUERSACHS R, Lee AYY, Kamphuisen PW, Meyer G, et al
    Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641150.
    PubMed     Abstract available
    
    
    
73. BOURGUIGNON T, Bernard A, Fauchier L
    Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641167.
    PubMed    
    
    
    
74. HUGON-RODIN J, Horellou MH, Conard J, Gompel A, et al
    Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
    Thromb Haemost. 2018 Apr 3. doi: 10.1055/s-0038-1641152.
    PubMed     Abstract available
    
    
    
75. GOLDMAN S, Fraczek P, Szklanny K, Papuga-Szela E, et al
    Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
    Thromb Haemost. 2018;118:654-663.
    PubMed     Abstract available
    
    
    March 2018
76. KHORANA AA, Weitz JI
    Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Thromb Haemost. 2018 Mar 22. doi: 10.1160/TH17-09-0681.
    PubMed     Abstract available
    
    
    
77. CAMM AJ
    The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Thromb Haemost. 2018 Mar 22. doi: 10.1055/s-0038-1632387.
    PubMed     Abstract available
    
    
    
78. BARBERO E, Bikdeli B, Chiluiza D, Barrios D, et al
    Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism.
    Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637746.
    PubMed    
    
    
    
79. LEHNERT P, Lange T, Moller CH, Olsen PS, et al
    Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality.
    Thromb Haemost. 2018;118:539-546.
    PubMed     Abstract available
    
    
    February 2018
80. LUTSEY PL, Horvath KJ, Fullam L, Moll S, et al
    Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1625985.
    PubMed     Abstract available
    
    
    
81. MARTOS L, Ramon LA, Oto J, Fernandez-Pardo A, et al
    alpha2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:alpha2M Levels Are Associated with Venous Thromboembolism.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1629902.
    PubMed     Abstract available
    
    
    
82. VAN DER POL LM, van der Hulle T, Mairuhu ATA, Huisman MV, et al
    Combination of Pulmonary Embolism Rule-out Criteria and YEARS Algorithm in a European Cohort of Patients with Suspected Pulmonary Embolism.
    Thromb Haemost. 2018 Feb 1. doi: 10.1055/s-0038-1623535.
    PubMed     Abstract available
    
    
    
83. SPRONK HMH, Padro T, Siland JE, Prochaska JH, et al
    Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
    Thromb Haemost. 2018;118:229-250.
    PubMed     Abstract available
    
    
    
84. VAN VULPEN LFD, Amin SN, Makris M
    Severe Wound Healing Impairment in a Patient with Dysfibrinogenaemia.
    Thromb Haemost. 2018;118:430-432.
    PubMed    
    
    
    January 2018
85. BIKDELI B, Jimenez D, Hawkins M, Ortiz S, et al
    Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).
    Thromb Haemost. 2018;118:214-224.
    PubMed     Abstract available
    
    
    
86. BLONDON M, Spirk D, Kucher N, Aujesky D, et al
    Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients.
    Thromb Haemost. 2018;118:82-89.
    PubMed     Abstract available
    
    
    December 2017
87. KLOK FA, Ageno W, Barco S, Binder H, et al
    Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Thromb Haemost. 2017;117:2425-2434.
    PubMed    
    
    
    
88. MEDINA A, Raskob G, Ageno W, Cohen AT, et al
    Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2017;117:2406-2414.
    PubMed    
    
    
    
89. RAUZI F, Smyth E, Emerson M
    Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.
    Thromb Haemost. 2017;117:2283-2290.
    PubMed    
    
    
    
90. BYKOV K, Bohn RL, Ewenstein BM, Seeger JD, et al
    Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
    Thromb Haemost. 2017;117:2267-2273.
    PubMed    
    
    
    
91. LEE LH, Gallus A, Jindal R, Wang C, et al
    Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review.
    Thromb Haemost. 2017;117:2243-2260.
    PubMed    
    
    
    November 2017
92. HALTON JML, Picard AC, Harper R, Huang F, et al
    Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Thromb Haemost. 2017;117:2168-2175.
    PubMed     Abstract available
    
    
    
93. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117:2163-2167.
    PubMed     Abstract available
    
    
    
94. KHORANA AA, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117:2135-2145.
    PubMed     Abstract available
    
    
    
95. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117:2045-2052.
    PubMed     Abstract available
    
    
    October 2017
96. BASS AR, Fields KG, Goto R, Turissini G, et al
    Clinical Decision Rules for Pulmonary Embolism in Hospitalized Patients: A Systematic Literature Review and Meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Abstract available
    
    
    
97. VAN OMMEN CH, Klaassen ILM, van Els AL, van de Wetering MD, et al
    Increasing Incidence and Recurrence Rate of Venous Thromboembolism in Paediatric Oncology Patients in One Single Centre Over 25 Years.
    Thromb Haemost. 2017;117.
    PubMed     Abstract available
    
    
    
98. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117.
    PubMed     Abstract available
    
    
    
99. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117.
    PubMed     Abstract available
    
    
    September 2017
100. KHORANA A, Vadhan-Raj S, Kuderer NM, Wun T, et al
     Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
101. SCHULMAN S
     Accumulating data on rivaroxaban for venous thromboembolism in clinical practice.
     Thromb Haemost. 2017;117.
     PubMed    
     
     
     August 2017
102. SEILER E, Limacher A, Mean M, Beer HJ, et al
     Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
103. MCBANE RD, Loprinzi CL, Ashrani A, Perez-Botero J, et al
     Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
104. BLEKER SM, Brekelmans MPA, Eerenberg ES, Cohen AT, et al
     Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
105. ANETSBERGER A, Blobner M, Haller B, Schmid S, et al
     Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
106. TAKACH LAPNER S, Julian JA, Linkins LA, Bates S, et al
     Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
107. JANION-SADOWSKA A, Natorska J, Siudut J, Zabczyk M, et al
     Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     June 2017
108. COLEMAN CI, Coleman C, Bunz TJ, Turpie AGG, et al
     Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     
109. SCHULMAN S, Ageno W, Konstantinides SV
     Venous thromboembolism: Past, present and future.
     Thromb Haemost. 2017;117:1219-1229.
     PubMed     Abstract available
     
     
     
110. VAN DER HULLE T, van Es N, den Exter P, van Es J, et al
     Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis.
     Thromb Haemost. 2017;117.
     PubMed     Abstract available
     
     
     May 2017
111. CHUNG WS, Lin CL
     Increased risks of venous thromboembolism in patients with psoriasis. A Nationwide Cohort Study.
     Thromb Haemost. 2017 May 24. doi: 10.1160/TH17-01-0039.
     PubMed     Abstract available
     
     
     April 2017
112. SANTI RM, Ceccarelli M, Bernocco E, Monagheddu C, et al
     Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
     Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895.
     PubMed     Abstract available
     
     
     
113. SCHULMAN S, Singer D, Ageno W, Casella IB, et al
     NOACs for treatment of venous thromboembolism in clinical practice.
     Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH17-01-0065.
     PubMed     Abstract available
     
     
     
114. COHEN AT, Gitt AK, Bauersachs R, Fronk EM, et al
     The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
     Thromb Haemost. 2017 Apr 13. doi: 10.1160/TH16-10-0793.
     PubMed     Abstract available
     
     
     March 2017
115. RAJPURKAR M, Biss T, Amankwah E, Martinez D, et al
     Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
     Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-07-0529.
     PubMed     Abstract available
     
     
     
116. SINDET-PEDERSEN C, Langtved Pallisgaard J, Staerk L, Gerds TA, et al
     Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
     Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-10-0745.
     PubMed     Abstract available
     
     
     
117. TAFUR AJ, Caprini JA, Cote L, Trujillo-Santos J, et al
     Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
     Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0840.
     PubMed     Abstract available
     
     
     
118. KLOK FA, Barco S, Konstantinides SV
     External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
     Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-10-0810.
     PubMed     Abstract available
     
     
     February 2017
119. 
     Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
     Thromb Haemost. 2017;117:643.
     PubMed    
     
     
     
120. DENTALI F, Mumoli N, Prisco D, Fontanella A, et al
     Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
     Thromb Haemost. 2017;117:606-617.
     PubMed     Abstract available
     
     
     
121. DING Q, Yang L, Zhao X, Wu W, et al
     Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.
     Thromb Haemost. 2017;117:479-490.
     PubMed     Abstract available
     
     
     
122. HEIT JA, Armasu SM, McCauley BM, Kullo IJ, et al
     Identification of unique venous thromboembolism-susceptibility variants in African-Americans.
     Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652.
     PubMed     Abstract available
     
     
     
123. BREKELMANS MP, Scheres LJ, Bleker SM, Hutten BA, et al
     Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
     Thromb Haemost. 2017 Feb 9. doi: 10.1160/TH16-11-0874.
     PubMed     Abstract available
     
     
     
124. STUCK AK, Spirk D, Schaudt J, Kucher N, et al
     Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review.
     Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-08-0631.
     PubMed     Abstract available
     
     
     
125. BOCHENEK ML, Rosinus NS, Lankeit M, Hobohm L, et al
     From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.
     Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0790.
     PubMed     Abstract available
     
     
     January 2017
126. CHAI-ADISAKSOPHA C, Linkins LA, ALKindi SY, Cheah M, et al
     Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
     Thromb Haemost. 2017 Jan 12. doi: 10.1160/TH16-09-0680.
     PubMed     Abstract available
     
     
     
127. ZHAO B, Zhang Y, Huang Y, Yu J, et al
     A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
     Thromb Haemost. 2017;117:44-56.
     PubMed     Abstract available
     
     
     December 2016
128. HEIT JA, Ashrani A, Crusan DJ, McBane RD, et al
     Reasons for the persistent incidence of venous thromboembolism.
     Thromb Haemost. 2016.
     PubMed     Abstract available
     
     
     November 2016
129. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
     Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
     Thromb Haemost. 2016.
     PubMed     Abstract available
     
     
     
130. AY C, Pabinger I, Cohen AT
     Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
     Thromb Haemost. 2016.
     PubMed     Abstract available
     
     
     
131. AGENO W, Casella I, Han CK, Raskob GE, et al
     RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
     Thromb Haemost. 2016.
     PubMed     Abstract available
     
     
     October 2016
132. TRUJILLO-SANTOS J, Di Micco P, Dentali F, Douketis J, et al
     Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
     Thromb Haemost. 2016.
     PubMed     Abstract available
     
     
     
133. RIEDL J, Kaider A, Marosi C, Prager GW, et al
     Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
     Thromb Haemost. 2016;117.
     PubMed     Abstract available
     
     
     
134. AMBROSINO P, Tarantino L, Di Minno G, Paternoster M, et al
     The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.
     Thromb Haemost. 2016;117.
     PubMed     Abstract available
     
     
     
135. 
     Venous thromboembolism: A Call for risk assessment in all hospitalised patients.
     Thromb Haemost. 2016;116:777-779.
     PubMed    
     
     
     
136. COHEN AT, Katholing A, Rietbrock S, Bamber L, et al
     Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
     Thromb Haemost. 2016;117.
     PubMed     Abstract available
     
     
     September 2016
137. 
     Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
     Thromb Haemost. 2016;116:775.
     PubMed     Abstract available
     
     
     
138. WEITZ JI, Haas S, Ageno W, Angchaisuksiri P, et al
     Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
     Thromb Haemost. 2016;116.
     PubMed     Abstract available
     
     
     
139. CAPPATO R, Welsh R
     Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
     Thromb Haemost. 2016;116.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Venous Thrombosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: